Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Ray-Coquard, I.;Leary, A.;Pignata, S.;Cropet, C.;González-Martín, A.;Marth, C.;Nagao, S.;Vergote, I.;Colombo, N.;Mäenpää, J.;Selle, F.;Sehouli, J.;Lorusso, D.;Guerra Alia, E. M.;Bogner, G.;Yoshida, H.;Lefeuvre-Plesse, C.;Buderath, P.;Mosconi, A. M.;Lortholary, A.;Burges, A.;Medioni, J.;El-Balat, A.;Rodrigues, M.;Park-Simon, T. -W.;Dubot, C.;Denschlag, D.;You, B.;Pujade-Lauraine, E.;Harter, P.

2023-01-01